CN108349971A - 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途 - Google Patents

咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途 Download PDF

Info

Publication number
CN108349971A
CN108349971A CN201680063688.5A CN201680063688A CN108349971A CN 108349971 A CN108349971 A CN 108349971A CN 201680063688 A CN201680063688 A CN 201680063688A CN 108349971 A CN108349971 A CN 108349971A
Authority
CN
China
Prior art keywords
methyl
phenyl
quinoline
imidazo
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680063688.5A
Other languages
English (en)
Chinese (zh)
Inventor
K.G.派克
B.C.巴拉姆
T.A.亨特
A.J.伊瑟顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN108349971A publication Critical patent/CN108349971A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680063688.5A 2015-11-03 2016-11-02 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途 Pending CN108349971A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1519406.1A GB201519406D0 (en) 2015-11-03 2015-11-03 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB1519406.1 2015-11-03
PCT/EP2016/076412 WO2017076895A1 (en) 2015-11-03 2016-11-02 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CN108349971A true CN108349971A (zh) 2018-07-31

Family

ID=55130605

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680063688.5A Pending CN108349971A (zh) 2015-11-03 2016-11-02 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途

Country Status (20)

Country Link
US (1) US20180318287A1 (enExample)
EP (1) EP3371183A1 (enExample)
JP (1) JP2018536649A (enExample)
KR (1) KR20180070703A (enExample)
CN (1) CN108349971A (enExample)
AU (1) AU2016348546B2 (enExample)
BR (1) BR112018007772A2 (enExample)
CA (1) CA3002608A1 (enExample)
CL (1) CL2018001146A1 (enExample)
CO (1) CO2018003969A2 (enExample)
CR (1) CR20180307A (enExample)
GB (1) GB201519406D0 (enExample)
HK (2) HK1255598A1 (enExample)
IL (1) IL258818A (enExample)
MX (1) MX2018005445A (enExample)
PE (1) PE20181345A1 (enExample)
PH (1) PH12018500958A1 (enExample)
RU (1) RU2018120318A (enExample)
SV (1) SV2018005663A (enExample)
WO (1) WO2017076895A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020063855A1 (zh) * 2018-09-30 2020-04-02 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN113508118A (zh) * 2019-03-05 2021-10-15 阿斯利康(瑞典)有限公司 用作抗癌剂的稠合三环化合物
WO2023143282A1 (zh) * 2022-01-26 2023-08-03 正大天晴药业集团股份有限公司 含有肼基的化合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2019057757A1 (en) 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
ES3001444T3 (en) 2018-09-14 2025-03-05 Suzhou Zanrong Pharma Ltd 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
WO2021098734A1 (zh) * 2019-11-19 2021-05-27 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor
CN116056698B (zh) * 2020-09-21 2024-11-19 威尚（上海）生物医药有限公司 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes
US20250179067A1 (en) * 2022-04-11 2025-06-05 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative crystal form, salt crystal form, preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139747A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CN102372711A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
RS62082B1 (sr) * 2015-04-02 2021-08-31 Merck Patent Gmbh Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139747A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CN102372711A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020063855A1 (zh) * 2018-09-30 2020-04-02 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
CN112771045A (zh) * 2018-09-30 2021-05-07 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
US11230549B2 (en) 2018-09-30 2022-01-25 Medshine Discovery Inc. Quinolino-pyrrolidin-2-one derivative and application thereof
CN112771045B (zh) * 2018-09-30 2022-04-19 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
CN113508118A (zh) * 2019-03-05 2021-10-15 阿斯利康(瑞典)有限公司 用作抗癌剂的稠合三环化合物
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN115380031A (zh) * 2020-03-30 2022-11-22 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
WO2023143282A1 (zh) * 2022-01-26 2023-08-03 正大天晴药业集团股份有限公司 含有肼基的化合物

Also Published As

Publication number Publication date
SV2018005663A (es) 2018-07-20
MX2018005445A (es) 2018-08-14
KR20180070703A (ko) 2018-06-26
US20180318287A1 (en) 2018-11-08
CL2018001146A1 (es) 2018-09-04
CO2018003969A2 (es) 2018-07-10
RU2018120318A (ru) 2019-12-05
CR20180307A (es) 2018-10-05
WO2017076895A1 (en) 2017-05-11
JP2018536649A (ja) 2018-12-13
PE20181345A1 (es) 2018-08-22
RU2018120318A3 (enExample) 2019-12-24
CA3002608A1 (en) 2017-05-11
EP3371183A1 (en) 2018-09-12
AU2016348546A1 (en) 2018-06-14
PH12018500958A1 (en) 2018-11-19
HK1257678A1 (zh) 2019-10-25
BR112018007772A2 (pt) 2018-10-30
AU2016348546B2 (en) 2019-05-02
GB201519406D0 (en) 2015-12-16
IL258818A (en) 2018-06-28
HK1255598A1 (zh) 2019-08-23

Similar Documents

Publication Publication Date Title
CN108349971A (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
DK3140303T3 (en) IMIDAZO [4,5-C] QUINOLIN-2 COMPOUNDS AND ITS USE IN TREATMENT OF CANCER
CN108348515A (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
CN108137576B (zh) 8-[6-[3-(氨基)丙氧基]-3-吡啶基]-1-异丙基-咪唑并[4，5-c]喹啉-2-酮衍生物
TW201837045A (zh) 胺基-三唑并吡啶化合物及其在治療癌症中之用途
KR101496273B1 (ko) 1,7-디아자카르바졸 및 암 치료에서의 그 용도
TW201805284A (zh) 咪唑并［4，5－c］喹啉－2酮化合物及其治療癌症之用途
CN106536524B (zh) 用于在增殖性疾病的治疗中使用的[1,2,4]三唑并[4,3-b]哒嗪
TW201808948A (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它們在治療癌症中之用途
CN111344293A (zh) 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
HK40016607A (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HK1232528B (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HK1232528A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HK1255408B (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives
BR112016025153B1 (pt) "compostos de imidazo[4,5-c]quinolin-2-ona, composição farmaceutica e seu uso no tratamento de câncer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257678

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1257678

Country of ref document: HK